Early use of vedolizumab vs. infliximab in biologic-naive patients with ulcerative colitis: A real-world analysis of healthcare utilisation

被引：0
|
作者：
Patel, H. [1 ]
Khalid, J. M. [1 ]
Shah, S. [2 ]
Shah, R. [3 ]
Berger, A. [2 ]
机构：
[1] Takeda Dev Ctr Europe Ltd, Evidence & Value Generat, London, England
[2] Evidera, Real World Evidence, Waltham, MA USA
[3] Evidera, Real World Evidence, London, England
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P552
引用
收藏
页码：S385 / S386
页数：2
相关论文
共 50 条
  • [31] Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (01) : 45 - 54
  • [32] Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced
    Megna, Matteo
    Ruggiero, Angelo
    Torta, Ginevra
    Martora, Fabrizio
    Bianco, Mariateresa
    Potestio, Luca
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (10) : 1186 - 1189
  • [33] COST-EFFECTIVENESS COMPARISON OF VEDOLIZUMAB, INFLIXIMAB AND CONVENTIONAL THERAPY FOR THE TREATMENT OF BIOLOGIC-NAIVE, MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS IN CHINA
    Sheng, Y.
    Ma, L.
    Chen, J.
    Xie, L.
    Zhao, W.
    Han, Y.
    VALUE IN HEALTH, 2020, 23 : S533 - S533
  • [34] Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis
    Durak, Muhammed B.
    Cagir, Yavuz
    Yuksel, Ilhami
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2025, 31 (01): : 22 - 27
  • [35] Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    Khilfeh, Ibrahim
    Curtis, Jeffrey R.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (11) : 767 - 779
  • [36] Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naive and biologic-experienced patients with ulcerative colitis in France
    Oppe, Mark
    Muresan, Bogdan
    Chan, Katie
    Radu, Xenia
    Schultz, Bob G.
    Turpin, Robin S.
    Nucit, Arnaud
    Fenu, Elisabetta
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (02) : 205 - 213
  • [37] Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naive Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study
    Yarur, Andres
    Mantzaris, Gerassimos J.
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Lissoos, Trevor
    Lopez, Claudia
    Natsios, Athanasios
    Kifnidi, Christina
    Saha, Sumit
    Demuth, Dirk
    Patel, Haridarshan
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S460 - S461
  • [38] Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
    Haraoui, B.
    Pope, Janet E.
    Fortin, Isabelle
    Rampakakis, Emmanouil
    Sampalis, John S.
    Romeyer, Francoise
    Atallah, Joseph
    Bessette, Louis
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [39] Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
    Haraoui, Boulos
    Pope, Janet
    Fortin, Isabelle
    Rampakakis, Emmanouil
    Sampalis, John
    Romeyer, Francoise
    Atallah, Joseph
    Bessette, Louis
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (07) : 1054 - 1054
  • [40] REAL-WORLD COMPARISON OF ARTHRALGIAS WITH INFLIXIMAB VS. VEDOLIZUMAB IN THE TREATMENT OF BIO-NAIVE INFLAMMATORY BOWEL DISEASE
    Ritter, Timothy
    Fourment, Chris
    Kuten, Samantha
    Van Anglen, Lucinda
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S3 - S3
12345